World Science

NONINVASIVE METHOD FOR MAPPING BURIED COAL ASH

2025-09-28T02:14:21+00:00

Coal Combustion Products (CCP) are one of the largest industrial waste streams in the world and, in some cases, the final disposition of this toxic material is not carefully controlled resulting in undocumented landfills, illegal dump sites, and mixing with Municipal Solid Waste (MSW). A new approach for discovering and mapping CCP sites based on radiation measurements has been tested in a historicaly inducstrial on the east coast of the United States where CCP was extensively used as fill material.

PRACTICAL ASPECTS OF THE USE OF FLY ASH DURING COLD RECYCLING OF ROAD CLOTHING

2025-10-01T14:33:30+00:00

The article examines the use of fly ash in materials produced by cold recycling technology. The ecological problem that arises during the storage of ash and slag materials has been studied. The question of the use of fly ash in road construction was considered. The composition of the mixture was selected, the consumption of materials was determined, samples were formed, which were then tested for compliance of their physical and mechanical characteristics with the requirements of national standards. After the arrangement of the experimental site, a number of field tests were conducted. Based on the results of research, it was established that fly ash mixtures meet the requirements of current regulatory documents in terms of their physical and mechanical properties and have characteristics no worse than mixtures made using the classic cold recycling technology.

MODULATING GLUTEN-TRIGGERED IMMUNITY: THE NEXT STEP IN CELIAC DISEASE TREATMENT

2025-09-13T20:31:43+00:00

Celiac disease (CeD) is an autoimmune condition triggered by gluten ingestion in genetically predisposed individuals. Although a strict gluten-free diet (GFD) remains the gold standard for treatment, many patients experience ongoing symptoms or fail to achieve mucosal healing due to inadvertent gluten exposure and challenges in long-term adherence. These limitations and growing understanding of the pathophysiology of CeD have prompted the development of non-dietary therapies that target the underlying immune mechanisms of CeD. Emerging therapeutic strategies aim to modulate gluten-triggered immunity, including the inhibition of tissue transglutaminase 2 (TG2), blockade of HLA-DQ2.5 and gluten peptide complexes, suppression of interleukin-15 (IL-15), and interference with gut-homing lymphocyte trafficking. Among these, the TG2 inhibitor ZED1227 has demonstrated the most advanced clinical efficacy, while IL-15–targeting agents such as AMG 714 and CALY-002 show promise, particularly in refractory CeD. However, to date, none of those novel immune-modulating strategies have yet demonstrated sufficient efficacy and safety to replace dietary therapy. Therefore, future well-designed, long-term studies are needed to validate the efficacy, safety, and cost-effectiveness of immune-mediated therapies and to define their role in personalized management of CeD.